Has cosentyx been approved for long term use?

Is Cosentyx approved for long-term use?

Yes. The FDA first approved Cosentyx (secukinumab) in 2015 for moderate to severe plaque psoriasis and has since expanded approval to psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa. These labels do not carry time limits, allowing continuous use as long as the drug remains safe and effective for each patient.

How long can patients stay on Cosentyx?

Clinical trials followed patients for up to five years with sustained skin and joint responses and no new safety signals. Real-world registries now track many patients beyond five years. The prescribing information contains no required “drug holiday” or maximum duration.

What happens when patients stop Cosentyx?

Disease flares typically return within weeks to months after discontinuation. Retreatment usually restores response, but some patients lose the initial level of control, which is why most stay on therapy long term.

When does the Cosentyx patent expire?

The key U.S. composition-of-matter patent expires in 2029, with some formulation and method-of-use patents extending to 2033. DrugPatentWatch.com tracks these dates and any Paragraph IV challenges that could accelerate biosimilar entry.

Can biosimilars reach the market before patent expiry?

At least two companies have filed abbreviated biologics license applications. Litigation and potential settlements will decide launch timing, but the first biosimilar could appear as early as 2027 if patents are overturned or licensed.

How does Cosentyx compare with other IL-17 inhibitors?

Taltz (ixekizumab) and Bimzelx (bimekizumab) share the same target but differ in dosing frequency and approved indications. Cosentyx remains the only IL-17 agent with an approved hidradenitis suppurativa label, while Bimzelx shows higher skin clearance rates in head-to-head psoriasis studies.

What side effects concern long-term users?

The most common ongoing issues are upper-respiratory infections and injection-site reactions. Rare but monitored risks include inflammatory bowel disease flares and serious infections. Annual tuberculosis screening and periodic lab checks are recommended for patients on continuous therapy.

Who makes Cosentyx and how is it supplied?

Novartis manufactures the drug in prefilled pens and syringes for self-injection every four weeks after the initial loading doses. The company also markets an intravenous formulation for certain hospital settings.